BOSTON and ROCHESTER, N.Y., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Caliber Imaging & Diagnostics (OTCQB:LCDX) formerly Lucid, Inc., was featured in an article in the Boston Globe on October 14.
The article, titled "Laser imaging device makes no-cut biopsies possible," focuses on Caliber's VivaScope® devices and their success in enabling doctors to perform biopsies without cutting into skin and to determine relatively quickly if a patient has cancer. The article also briefly details VivaScope's rollout to hospitals and the Company's efforts to spur wider adoption of the devices.
Reporter Callum Borchers writes, "The result [of using VivaScope] is a high-resolution image that mimics what a pathologist would see under a microscope when examining a skin sample removed during a traditional biopsy. By studying cell structure, a doctor can determine whether a lesion is cancerous—often right away."
The article introduces a 26-year-old female patient who has undergone multiple biopsies resulting in scarring, but who has since found greater satisfaction in dermatologist visits after being introduced to VivaScope. Borchers also quotes Dr. Jane Grant-Kels, chair of the dermatology department at the University of Connecticut Health Center, who says of VivaScope, "Patients love it. Patients love any technology that will give the doc more information and avoid hurting them."
To read the Boston Globe article in its entirety, please visit the following link: http://www.bostonglobe.com/business/2013/10/13/laser-imaging-device-makes-cut-biopsies-possible/NhbRyPVJpG99dD2m5TkVpI/story.html
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics' platform of products offer increased productivity from the research laboratory to the doctor's office or the surgeon's operating room. Caliber I.D.'s platform of products provide precise accuracy, consistent reliability, and online backup that all combine to lead to better patient care. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.
This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
CONTACT: Richard Pulsifer Chief Financial Officer (617) 348-9821 Investor Relations: Dian Griesel Int'l. Cheryl Schneider (212) 825-3210 email@example.com Public Relations: Dian Griesel Int'l. Susan Forman or Laura Radocaj (212) 825-3210 firstname.lastname@example.org email@example.comSource:Caliber Imaging & Diagnostics, Inc.